Navigation Links
BioBehavioral Diagnostics Company to Present at Biotech Showcase™ 2011
Date:1/5/2011

PLYMOUTH MEETING, Pa., Jan. 5, 2011 /PRNewswire/ -- BioBehavioral Diagnostics Company (BioBDx), a privately held diagnostics company which manufactures and markets the Quotient® ADHD System, a tool that aids in the objective and accurate assessment of attention-deficit hyperactivity disorder (ADHD), announced today that Byron Hewett, executive chairman, has been selected to present at Biotech Showcase 2011 in San Francisco, CA.

Mr. Hewett's presentation will be given at the Parc 55 Wyndham Hotel on Tuesday, January 11, 2011 at 1:45 p.m. PST.  The presentation will also be available via web cast at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=W242090&item_id=3599550.

About the Quotient® ADHD SystemThe Quotient® ADHD System measures motion and analyzes shifts in attention state to give an objective picture of the core symptom areas of ADHD.  Clinicians use the Quotient® ADHD Test at the initial visit to assess severity of the three core symptoms of ADHD; hyperactivity, inattention and impulsivity.  Patients may be re-assessed periodically at follow-up visits to guide treatment plans.  The clinician integrates the Quotient® ADHD Test report with information from other assessment tools and the clinical evaluation to help guide the discussion on the treatment plan. For more information about the Quotient® ADHD System, please visit http://www.biobdx.com/Products/QuotientADHDSystem.aspx.

About BioBehavioral Diagnostics CompanyBioBDx manufactures and markets the Quotient® ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptom areas.  We are dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD.  Our vision is to provide accurate tools for the diagnosis and management of neurological and psychiatric conditions, leading to a transformation of behavioral medicine.  Founded in 2006, BioBehavioral Diagnostics is a privately held company.

Contacts:BioBDxByron Hewett

Executive Chairman

(610) 260-1492

Byron_Hewett@BioBDx.com

Media or Investors:Tiberend Strategic Advisors, Inc.

212-827-0020

Tamara Bright

tbright@tiberend.com or

Claire Sojda

csojda@tiberend.com
'/>"/>

SOURCE BioBehavioral Diagnostics Company
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds The 2011 Clinical Chemistry And Immunodiagnostics Markets US, Europe, Japan: Product Development Opportunities And Business Expansion Strategies For Instrument And Reagent Suppliers
2. Reportlinker Adds The 2011 Molecular Diagnostics Market: DNA Probes and Biochips New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
3. Reportlinker Adds The 2011 Cancer Diagnostics Market: US, Europe, Japan Emerging Opportunities and Business Expansion Strategies
4. Reportlinker Adds Molecular Diagnostics Markets
5. Reportlinker Adds Molecular Diagnostics - Technologies, Markets and Companies
6. Exagen Diagnostics Awarded $400,000 in Grants Under the QTDP Program
7. Quest Diagnostics® Care360™ EHR Receives ONC-ATCB 2011/2012 Certification
8. Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash
9. Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors
10. Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
11. The Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities in Personalized Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... 10, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer Jaye ... GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to achieving ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):